CD4+ T Cells Are Key to Shaping a Protective Humoral Immunity in Primary Dengue 2 Virus Infection: Implications for Rational Vaccine Design
Authors:
- Angel E. Miranda-SantiagoAMAngel E. Miranda-Santiago
- Crisanta Serrano-CollazoCSCrisanta Serrano-Collazo
- Lorna A. CruzLCLorna A. Cruz
- Sandra HeneinSHSandra Henein
- Laura AlvarezLALaura Alvarez
- Teresa AranaTATeresa Arana
- Jorge L. Sánchez-BibiloniJSJorge L. Sánchez-Bibiloni
- Melween I. MartinezMMMelween I. Martinez
- Chiara RomanCRChiara Roman
- Armando G. BurgosABArmando G. Burgos
- Marcos J. Ramos-BenitezMRMarcos J. Ramos-Benitez
- Lourdes M. Caro-RiveraLCLourdes M. Caro-Rivera
Open Access
Abstract
Background: Understanding the immune mechanisms that differentiate protective from pathogenic responses during dengue virus (DENV) infection is critical for effective vaccine development. Objective: To investigate how CD4+ T cell depletion alters viral control and the humoral immune response during primary DENV2 infection in a non-human primate (NHP) model. Methods: Rhesus macaques were depleted of CD4+ T cells prior to DENV2 infection. Viral kinetics, B cell activation, antibody specificity, and functional outcomes were evaluated longitudinally, including cross-reactivity and antibody-dependent enhancement (ADE) potential. Results: CD4+ T cells were essential for early viral clearance and the generation of robust, type-specific neutralizing antibodies. In their absence, animals exhibited early non-specific polyclonal B cell activation, delayed isotype switching, and an expanded repertoire of cross-reactive antibodies to DENV and Zika virus (ZIKV), with diminished neutralizing capacity. CD4-depleted macaques also showed increased ADE potential, particularly against ZIKV, and elevated anti-NS1 IgG titers that persisted one-year post-infection. Conclusion: CD4+ T cells play a critical role in orchestrating effective, durable, and type-specific antibody responses during primary DENV infection. Their absence leads to delayed antibody maturation, greater cross-reactivity, and higher ADE potential. These findings emphasize the need for DENV and ZIKV vaccines to include CD4+ T cell epitopes that promote high-quality, type-specific antibody responses and minimize ADE risk.Keywords
All Related Versions
Funding Information
- NIH (5R01AI 148264-05, 2 P40 OD012217-38, 2U42OD021458-23, 5-U24-AI152170-04)
- NIGMS- RISE program (R25GM061838)
This publication has 94 references indexed in Scilit:
- Global re-emergence of dengue fever: The need for a rapid response and surveillanceThe Microbe, 2024
- Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variantCell Reports, 2022
- Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated ProtectionCell Host & Microbe, 2021
- Protective and enhancing interactions among dengue viruses 1-4 and Zika virusCurrent Opinion in Virology, 2020
- Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forwardVaccine, 2015
- Dengue Virus Infection Induces Expansion of a CD14+CD16+ Monocyte Population that Stimulates Plasmablast DifferentiationCell Host & Microbe, 2014
- Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infectionArchives of Virology, 2013
- Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaquesImmunogenetics, 2011
- Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtypeVirology, 2009
- Selective CD4+ T Cell Help for Antibody Responses to a Large Viral Pathogen: Deterministic Linkage of SpecificitiesImmunity, 2008